Abstract: The invention relates to a polymer film having negative optical dispersion, novel polymerisable compounds and liquid crystal (LC) materials for its preparation, and the use of the polymer film and novel compounds and materials in optical, electrooptical, electronic, semiconducting or luminescent components or devices.
Type:
Grant
Filed:
March 4, 2008
Date of Patent:
October 16, 2012
Assignee:
Merck Patent GmbH
Inventors:
Owain Llyr Parri, Kevin Adlem, Karl Skjonnemand, David Wilkes
Abstract: The invention relates to an optically biaxial film comprising an anisotropic material with uniform helically twisted structure and a reflection wavelength below 400 nm, to methods and materials for its preparation, to its use as retardation or compensation film in optical devices like liquid crystal displays, and to compensators and liquid crystal displays comprising such a biaxial film.
Type:
Grant
Filed:
June 15, 2005
Date of Patent:
October 16, 2012
Assignee:
Merck Patent Gesellschaft mit Beschränkter Haftung
Inventors:
Mark Verrall, Kim Slaney, Owain Llyr Parri, Richard Harding, Shirley Ann Marden
Abstract: The present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above. The solubility is achieved by a mixture of solvents as described herein. Moreover the formulation as described herein may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.
Abstract: The invention relates to a method of preparing a reforming catalyst comprising a group VIII metal, a halogen, at least one metal selected from the group made up of the group VIIB metals and group IVA metals, a refractory oxide support. The method comprises stages of preparing a dry impregnation aqueous solution containing ammonia, either in solution or in gas form and a complexing agent, of aging the aqueous solution, of dry impregnation of the support, of maturing the impregnated support, of drying and of calcination.
Abstract: The present invention relates to the use of phosphinic acids and/or phosphonic acids and salts thereof, preferably as surface-active compounds, in redox processes, in particular in electroplating technology, particularly preferably in electroplating baths, and to electroplating baths comprising these compounds.
Abstract: The invention relates to a method of treating feedstocks from renewable sources without intermediate gas-liquid separation in order to produce diesel fuel bases of excellent quality. The feedstocks used can be raw vegetable oils or such oils that have been previously subjected to a prerefining stage, animal fats, or mixtures of such feedstocks. The invention relates to a method allowing high diesel fuel base yields to be obtained from such feedstocks.
Abstract: The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.
Type:
Grant
Filed:
December 13, 2011
Date of Patent:
October 2, 2012
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Wolfgang Schwede, Ulrich Klar, Carsten Moller, Andrea Rotgeri, Wilhelm Bone
Abstract: The invention concerns a method for optimizing the operation of a reaction section for hydrocarbon synthesis starting from a feed comprising synthesis gas, operated in the presence of a catalyst comprising cobalt. This method comprises the following steps: a) determining the theoretical molar ratio, PH2O:PH2, in the reaction section; b) optionally, adjusting the ratio PH2O:PH2 determined in step a) to a value strictly below 1; c) determining the new value for the theoretical ratio PH2O:PH2 in the reaction section; and repeating steps a) to c) until the ratio of the partial pressures of water and hydrogen, PH2O:PH2, has a value strictly less than 1.1.
Abstract: The invention relates to polymers comprising indenofluorene units or derivatives thereof, organic semiconductor (OSC) materials comprising them, their use in electronic or electrooptical devices, and devices comprising said polymers or materials.
Type:
Grant
Filed:
April 13, 2007
Date of Patent:
October 2, 2012
Assignee:
Merck Patent Gesellschaft mit Beschränkter Haftung
Abstract: The present invention relates to a liquid-crystalline medium based on a mixture of polar compounds having negative dielectric anisotropy (??), which is distinguished by the fact that it has a value for the ratio ?1/?n2 in the range 6-45 with a clearing point of >60° C. and a ?? of ??2.3. Media of this type are particularly suitable for electro-optical displays having active-matrix addressing based on the ECB, PA LCD, FFS or IPS effect.
Abstract: The invention relates to a liquid-crystalline medium of negative dielectric anisotropy based on a mixture of polar compounds, which comprises at least one compound selected from the group of the compounds of the formulae IA, IB and IC in which R1A, R2A, R1B, R2B, R1C, R2C, L, m, n, o, p and b have the meanings indicated in Claim 1, and to the use thereof for an active-matrix display, in particular based on the ECB, PALC, FFS or IPS effect.
Type:
Grant
Filed:
August 7, 2008
Date of Patent:
October 2, 2012
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Abstract: The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.
Type:
Grant
Filed:
November 20, 2008
Date of Patent:
October 2, 2012
Assignee:
Merck Patent Gesellschaft mit beschränkter Haftung
Inventors:
Ulrich Emde, Oliver Block, Kai Schiemann
Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPVI can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
Type:
Grant
Filed:
September 13, 2008
Date of Patent:
October 2, 2012
Assignee:
Merck Patent Gesellschaft mit Beschränkter Haftung
Inventors:
Markus Klein, Werner Mederski, Christos Tsaklakidis, Norbert Beier
Abstract: Disclosed are novel liquid-crystal compounds, processes and intermediates for the preparation thereof, the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, and to LC media and LC displays containing the same.
Type:
Grant
Filed:
January 15, 2010
Date of Patent:
September 25, 2012
Assignee:
Merck Patent Gesellschaft Mit Beschrankter Haftung
Inventors:
Axel Jansen, Detlef Pauluth, Bernd Fiebranz, Bernhard Rieger